Jim Cramer said on CNBC's Mad Money that Gilead Sciences, Inc. GILD is extremely undervalued, but he would rather buy Amgen, Inc.AMGN, because Gilead Sciences has to make an acquisition with the money it has on its balance sheet.
Cramer thinks the deal between Bayer and Monsanto Company MON isn't going to happen, because the farmers aren't going to let it happen.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in